propylene glycol and Eczema, Atopic

propylene glycol has been researched along with Eczema, Atopic in 9 studies

Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Number of Participants With Clinically Significant Body Temperature Values Meeting Pre-defined Criteria

Body temperature of participants was measured in degree Celsius. The normal body temperature value was >= 39 degree Celsius. (NCT03356977)
Timeframe: Baseline (Day 1) up to Day 29 (end of treatment)

Number of Participants With Clinically Significant Laboratory Parameters Meeting Pre-defined Criteria

Criteria: hematology: hemoglobin, hematocrit, erythrocytes < 0.8*lower limit of normal (LLN), platelets <0.5*LLN >1.75*upper limit of normal (ULN), leukocytes <0.6* LLN >1.5* ULN, lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes <0.8* LLN >1.2* ULN, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes monocytes monocytes/leukocytes >1.2*ULN. Clinical chemistry: bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase >3.0*ULN, protein, albumin <0.8* LLN >1.2* ULN, blood urea nitrogen, creatinine >1.3* ULN, sodium <0.95*LLN >1.05*ULN, potassium, chloride, bicarbonate <0.9* LLN >1.1* ULN, glucose <0.6*LLN >1.5*ULN. (NCT03356977)
Timeframe: Baseline (Day 1) up to Day 29 (end of treatment)

Number of Participants With Clinically Significant Blood Pressure Values Meeting Pre-defined Criteria

Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) of participants was measured in terms of millimeters of mercury (mmHg). The clinically significant pre-defined criteria were, SBP: change of greater than equal to (>=) 30 mmHg increase from baseline (IFB) and SBP change of >= 30 mmHg decrease from baseline (DFB); DBP: change of >=20 mmHg IFB and DBP change of >=20 mmHg DFB. (NCT03356977)
Timeframe: Baseline (Day 1) up to Day 29 (end of treatment)

Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values Meeting Pre-defined Criteria

ECG of participants was measured in terms of millisecond (msec). ECG parameters included pulse rate (PR) interval, QRS interval, corrected QT interval using Fridericia's formula (QTcF). ECG values meeting pre-defined criteria were 1) PR interval: greater than equal to (>=) 25 percent (%) increase when baseline greater than (>)200 milliseconds (msec); or increase >=50% when baseline less than or equal to (<=200) msec; 2) QRS interval: >=25% increase when baseline >100 msec; >=50% increase when baseline <= 100 msec; 3) QTCF interval: QTc interval using Fridericia's formula (QTcF interval) > 30 msec. IFB stands for increase from baseline. (NCT03356977)
Timeframe: Baseline (Day 1) up to Day 29 (end of treatment)

Number of Participants With Clinically Significant Height Values Meeting Pre-defined Criteria

Height of participants was measured in terms of centimeter (cm). The pre-defined criteria for measuring the height was less than (<) 55 cm and greater than (>) 92.5 cm. (NCT03356977)
Timeframe: Baseline (Day 1) up to Day 29 (end of treatment)

Number of Participants With Clinically Significant Pulse Rate Values Meeting Pre-defined Criteria

Pulse rate of participants was measured in terms of beats per minute (bpm). The pre-defined criteria of measuring the pulse rate of participants was <90 bpm and >180 bpm. (NCT03356977)
Timeframe: Baseline (Day 1) up to Day 29 (end of treatment)

Number of Participants With Clinically Significant Respiratory Rate Values Meeting Pre-defined Criteria

Respiratory rate was measured in terms of number of breaths per minute. The pre-defined criteria of measuring the respiratory rate of participants was < 22 breaths per min and > 53 breaths per min. (NCT03356977)
Timeframe: Baseline (Day 1) up to Day 29 (end of treatment)

Number of Participants With Clinically Significant Weight Values Meeting Pre-defined Criteria

Weight of participants was measured in terms of kilogram (kg). The pre-defined criteria of measuring the weight of participants was less than equal to (<=) 4.5 kg and >15 kg. (NCT03356977)
Timeframe: Baseline (Day 1) up to Day 29 (end of treatment)

Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Site Reactions

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Site reactions are reactions which occurred in participants at the site of application of investigational product. (NCT03356977)
Timeframe: Baseline (Day 1) up to at least 28 days after last dose of investigational product (up to 60 days)

Reviews

1 review available for propylene glycol and Eczema, Atopic

Trials

2 trials available for propylene glycol and Eczema, Atopic

Other Studies

6 other studies available for propylene glycol and Eczema, Atopic